{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-031235","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.277168+00:00","generated_at":"2026-06-21T23:33:21.136075+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Anebulo Pharma Q1 FY2023 net loss $2.6M ($0.11/sh); positive ANEB-001 Phase 2 data","bullets":["Net loss $2.6M vs $1.6M YoY; diluted EPS ($0.11) vs ($0.07).","Cash $19.2M at Sept 30, 2022; cash burn $2.0M in quarter.","Positive interim data for ANEB-001 from Phase 2 Part B announced.","Closed $6.6M private placement financing in September 2022.","Appointed Nat Calloway, Ph.D. to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-031235","json":"https://secwatch.observer/filing/0001493152-22-031235.json","markdown":"https://secwatch.observer/filing/0001493152-22-031235.md","text":"https://secwatch.observer/filing/0001493152-22-031235.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315222031235/0001493152-22-031235-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315222031235/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:33:21.136075+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"30161b7b6fe57f08b6d68e4d5fd97c5b095a6103","claim":"Anebulo Pharmaceuticals, Inc. reported the three months ended September 30, 2022 results: net income $(0.11) per share, EPS $(0.11) per share.","evidence_excerpt":"Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815974/000149315222031235/0001493152-22-031235-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Net income","value":"$(0.11) per share"},{"label":"EPS","value":"$(0.11) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}